Equillium

Equillium, Inc. is a clinical-stage biotechnology company founded with the mission to develop innovative solutions for severe autoimmune and inflammatory disorders. Based in California, the company's vision centers on leveraging a deep understanding of immunobiology to create treatments that restore immune system balance. Equillium focuses on addressing high unmet medical needs through its pioneering products, including those currently in clinical trials for conditions such as acute graft-versus-host disease.

Notable figures affiliated with Equillium include its leadership team and scientific advisors, who bring extensive expertise in immunobiology and drug development. The company has attracted significant investment from prominent biotech investors, underscoring confidence in its potential. Key achievements include advancing multiple drug candidates into clinical trials and demonstrating promising efficacy and safety profiles. Equillium's impact lies in its commitment to transforming the lives of patients suffering from debilitating autoimmune and inflammatory conditions.